Eflornithine is a prescription drug indicated in the treatment of facial hirsutism (excessive hair growth). Eflornithine hydrochloride cream for topical application is intended for use in women suffering from facial hirsutism and is sold by Allergan, Inc. under the brand name Vaniqa. Eflornithine for injection against sleeping sickness was manufactured by Sa...
Eflornithine is indicated in the treatment of facial hirsutism (excessive hair growth).
Connecticut Children's Hospital, Hartford, Connecticut, United States
Arkansas Children's Hospital, Little Rock, Arkansas, United States
Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Sydney Childrens Hospital KCC, Randwick, Australia
Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States
CRT (Centre de Réference et de Traitement) Dipumba, Dipumba general hospital, Mbuji Mayi, East Kasai, Congo
HGR ISANGI hospital, Isangi, Province Orientale, Congo
Masi Manimba Hospital, Masi Manimba, Bandundu - DRC, Congo
Emory University, Atlanta, Georgia, United States
Cleveland Clinic, Cleveland, Ohio, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Connecticut Children's Hospital, Hartford, Connecticut, United States
Levine Children's Hospital, Charlotte, North Carolina, United States
UVM/FAHC, Burlington, Vermont, United States
University of Illinois College of Medicine - Chicago, Chicago, Illinois, United States
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Mayo Clinic, Rochester, Minnesota, United States
MSF-Belgium; PNLTHA, Epicentre, Isangi, Congo, The Democratic Republic of the
PNLTHA, STI, Epicentre, Mbuyi Maji, Congo, The Democratic Republic of the
MSF-Holland, Nkayi, RoC, Congo
University of California Medical Center At Irvine-Orange Campus, Orange, California, United States
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.